Literature DB >> 28509181

Use of darbepoetin alfa for myelodysplastic syndrome coincident with chronic kidney disease.

Kei Nagai1, Kunihiro Yamagata2.   

Abstract

Entities:  

Year:  2016        PMID： 28509181      PMCID： PMC5413747          DOI： 10.1007/s13730-016-0212-7

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN： 2192-4449


× No keyword cloud information.
  4 in total

1.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

Authors:  David Bowen; Dominic Culligan; Simon Jowitt; Stephen Kelsey; Ghulam Mufti; David Oscier; Jane Parker
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998

2.  Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.

Authors:  S Kuriyama; H Tomonari; H Yoshida; T Hashimoto; Y Kawaguchi; O Sakai
Journal:  Nephron       Date:  1997       Impact factor: 2.847

Review 3.  Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.

Authors:  Suetonia C Palmer; Sankar D Navaneethan; Jonathan C Craig; David W Johnson; Marcello Tonelli; Amit X Garg; Fabio Pellegrini; Pietro Ravani; Meg Jardine; Vlado Perkovic; Giusi Graziano; Richard McGee; Antonio Nicolucci; Gianni Tognoni; Giovanni F M Strippoli
Journal:  Ann Intern Med       Date:  2010-06-24       Impact factor: 25.391

4.  Chapter 3: Use of ESAs and other agents to treat anemia in CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-08
  4 in total
  1 in total

1.  Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report.

Authors:  Tatsuyoshi Ikenoue; Hiroshi Naito; Tetsuya Kitamura; Hideki Hattori
Journal:  J Med Case Rep       Date:  2017-10-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.